Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
This study is ongoing, but not recruiting participants.
Study NCT00192621 Information provided by The National Centre in HIV Epidemiology and Clinical Research
First Received: September 12, 2005 Last Updated: August 15, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Dyslipidemias
Glucose Metabolism Disorders
Metabolic Diseases
Lipodystrophy
Cardiovascular Disease
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Cardiovascular Diseases
Congenital Abnormalities
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Lipid Metabolism Disorders
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Skin Diseases
Skin Diseases, Metabolic
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Kaletra (lopinavir [LPVr])
Additional drug interventions recognized in this trial
Lopinavir
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
The National Centre in HIV Epidemiology and Clinical Research
St Vincent's Hospital, Sydney
National Heart, Lung, and Blood Institute (NHLBI)
Garvan Institute of Medical Research
Prince of Wales Hospital, Sydney
Back to top of Main Content
